jiayi-li23/proxann_data huggingface dataset:
Topic: Health — Drug Coverage and Cost
Subject: Armed forces and national security
Date: 2014-11-17 00:00:00

Clay Hunt Suicide Prevention for American Veterans Act or the Clay Hunt SAV Act - Requires the Secretary of Veterans Affairs (VA) and the Secretary of Defense (DOD) to each arrange for an independent third party evaluation of, respectively, the VA and DOD mental health care and suicide prevention programs.

Directs the VA Secretary to publish an Internet website that serves as a centralized source to provide veterans with regularly updated information regarding all of the VA's mental health care services.

Requires the VA Secretary and the DOD Secretary to enter into certain strategic relationships to facilitate:

 the mental health referrals of members of the reserve components who have a service-connected disability and are being discharged or released from the Armed Forces, timely behavioral health services for such members, communication when such members are at risk for behavioral health reasons, and the transfer of documentation for line-of-duty and fitness-for-duty determinations. Requires the VA Secretary to carry out a three-year pilot program to repay the education loans relating to psychiatric medicine that are incurred by individuals who:

 are eligible to practice psychiatric medicine in the Veterans Health Administration (VHA) or are enrolled in the final year of a residency program leading to a specialty qualification in psychiatric medicine, demonstrate a commitment to a long-term career as a psychiatrist in the VHA, and agree to a period of obligated service with the VHA in the field of psychiatric medicine in exchange for the repayment of such loans. Requires the DOD Secretary to submit to Congress a review of the staffing requirements for individual State National Guard Commands with respect to Directors of Psychological Health.

Authorizes the VA Secretary to collaborate with nonprofit mental health organizations to prevent suicide among veterans. Requires the collaborators to exchange training sessions, best practices, and other resources to enhance their suicide prevention efforts. Directs the Secretary to select a Director of Suicide Prevention Coordination within the VA to undertake any collaboration with nonprofit mental health organizations.
Topic: Health — Drug Coverage and Cost
Subject: Armed forces and national security
Date: 2015-01-20 00:00:00

Classified Veterans Access to Care Act

Requires the Secretary of Veterans Affairs (VA) to:

 establish standards and procedures to ensure that a veteran who participated in a classified mission or served in a sensitive unit while in the Armed Forces may access VA mental health care in a manner that fully accommodates the veteran's obligation to not improperly disclose classified information; disseminate guidance to employees of the Veterans Health Administration, including mental health professionals, on such standards and procedures and on how to best engage such veterans during the course of mental health treatment with respect to classified information; and ensure that an individual may elect to identify as such a veteran on an appropriate form.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-03-25 00:00:00

Patients' Access to Treatments Act of 2015

Amends the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure. Prohibits such a health plan from imposing higher cost-sharing requirements, including co-payment and co-insurance, for specialty drugs than for other prescription drugs in a non-preferred brand drug tier. Applies the non-preferred brand drug tier for which beneficiary cost-sharing is lowest, if a formulary used by the health plan contains more than one non-preferred brand drug tier.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-04-23 00:00:00

Medicare Drug Savings Act of 2015

 Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act (SSAct) to require drug manufacturers to pay the Secretary of Health and Human Services drug rebates for rebate eligible (low-income) individuals. Excludes from Medicare coverage as a part D drug any drug or biological manufactured by a manufacturer that has not entered into and have in effect a rebate agreement with the Secretary.

Requires a rebate agreement to require a drug or biological manufacturer to provide to the Secretary a rebate, determined according to a specified formula, for each rebate period ending after December 31, 2015, for any covered Medicare part D drug dispensed after that date to any rebate eligible individual for which payment was made by a prescription drug plan sponsor or MedicareAdvantage organization for such period.

Specifies a formula for determination of Medicaid rebate amounts for such drugs or biologicals.

Amends SSAct title XIX (Medicaid) to exclude any amounts paid under a rebate agreement from the determination of best price and average manufacturer price under the Medicaid program.
Topic: Health — Drug Coverage and Cost
Subject: Armed forces and national security
Date: 2015-04-28 00:00:00

Prescription Drug Accountability Act

This bill provides for Department of Veterans Affairs participation in state prescription drug monitoring programs.
Topic: Health — Drug Coverage and Cost
Subject: Government operations and politics
Date: 2015-04-30 00:00:00

FEHBP Prescription Drug Oversight and Cost Savings Act

 Prohibits the Office of Personnel Management (OPM) from entering a contract or approving a health benefits plan with a carrier that is a party to a pharmacy benefit manager (PBM) carrier arrangement to provide or administer prescription drug coverage under the Federal Employees Health Benefits Program (FEHBP) unless the PBM and the carrier comply with the requirements for PBM carrier arrangements set forth by this Act. Directs OPM to terminate a contract or discontinue a plan that fails to comply with such requirements.

Prohibits: (1) a PBM under a carrier arrangement from being under common corporate control with a prescription drug manufacturer or a retail pharmacy, and (2) OPM from permitting a carrier under common corporate control with a PBM to earn a profit from such control.

Sets forth terms and requirements for PBM carrier arrangements under the FEHBP, including: (1) drug substitution restrictions, (2) PBM reimbursement of carriers, (3) sale by a PBM of utilization and claims data, (4) drug pricing and the basis for reimbursement, (5) PBM provision to plan enrollees of an explanation of benefits statement regarding prescription drugs, (6) nondiscriminatory contracts regarding required participation, (7) OPM access to PBM contract information, and (8) civil monetary penalties for making false statements or claims to the government.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-06-03 00:00:00

Personal Drug Importation Fairness Act of 2015

This bill allows a drug to be imported by a person other than the drug's manufacturer if the drug: (1) has the same active ingredients, route of administration, and strength as an approved drug; (2) may be lawfully marketed in, and is imported or reimported from, a country included on a list in this Act that the Food and Drug Administration determines has standards for ensuring drug safety and effectiveness that are at least as protective as U.S. standards; (3) is dispensed by a licensed pharmacist; (4) is shipped directly to, or is imported by, the ultimate consumer; (5) is shipped or imported in quantities that do not exceed a 90-day supply; (6) is accompanied by a copy of a valid prescription; and (7) is not a controlled substance.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-07-14 00:00:00

Medicare Prescription Drug Price Negotiation Act of 2015

 Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to direct the Secretary of Health and Human Services to negotiate with pharmaceutical manufacturers the prices that may be charged to Medicare part D prescription drug plan (PDP) sponsors and MedicareAdvantage (MA) organizations for covered part D drugs for part D eligible individuals who are enrolled under a PDP or under an MA-Prescription Drug plan.
Topic: Health — Drug Coverage and Cost
Subject: Social welfare
Date: 2015-07-22 00:00:00

Foster Youth Independence Act of 2015 

This bill amends part E (Foster Care and Adoption Assistance) of title IV of the Social Security Act to allow the chief executive officer of a state to certify that the state will provide assistance and services under the John H. Chafee Foster Care Independence Program to youths who have aged out of foster care and have not attained age 23 if:

 the state has elected to extend the eligibility for foster care to all children up to age 21, or the responsible state agency uses state or other funds not provided under the Program to provide assistance and services comparable to those such youths would receive if the state had made such an election
Topic: Health — Drug Coverage and Cost
Subject: Commerce
Date: 2015-07-23 00:00:00

Fairness to Pet Owners Act of 2015

Directs the Federal Trade Commission to require prescribers of animal drugs to verify prescriptions and provide copies of prescriptions to pet owners, pet owner designees, and pharmacies, without the prescriber demanding payment or establishing other conditions. Applies these requirements to medication for a domesticated household animal that consumers are not allowed to purchase without a prescription.

Treats a violation of this Act as an unfair or deceptive act or practice under the Federal Trade Commission Act.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-07-28 00:00:00

Medicare Prescription Drug Savings and Choice Act of 2015

This bill amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to require the Centers for Medicare & Medicaid Services (CMS) to offer one or more Medicare-operated prescription drug plan options.  In doing so, CMS must: (1) negotiate prices with drug manufacturers; (2) establish an appeals process for denials of plan benefits, including the option for external review and determination by an independent entity; and (3) establish and apply a formulary and formulary incentives. In general, a Medicare-operated drug plan must meet the same requirements as apply to any other prescription drug plan.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-09-16 00:00:00

Prescription Drug Affordability Act of 2015

This bill amends titles XVIII (Medicare) and XIX (Medicaid) of the Social Security Act to modify provisions related to the affordability of prescription drugs under the Medicare and Medicaid programs. Specifically, the bill:

 requires the Centers for Medicare & Medicaid to negotiate lower prices on behalf of beneficiaries for drugs covered under Medicare Part D; accelerates closure of the Medicare Part D coverage gap known as the "donut hole," under which beneficiaries who have reached a certain level of yearly drug costs become fully responsible for any additional drug costs up to a certain limit; requires drug manufacturers to issue rebates for prescription drugs dispensed to eligible low-income individuals under Medicare or Medicaid; and expands the application of certain prescription drug rebate requirements under Medicaid to include rebates for generic drugs. The bill also amends the Federal Food, Drug, and Cosmetic Act to: (1) allow the importation by individuals of prescription drugs from Canada and, potentially, other countries; and (2) establish certain conditions on the award of market exclusivity with respect to drugs. Specifically, a drug manufacturer's market exclusivity shall be terminated if the manufacturer commits, or fails to report, a drug-related violation such as misbranding, illegal marketing, or fraud.

In addition, the bill amends the Federal Trade Commission Act to: (1) establish restrictions on certain anticompetitive patent settlements known as "pay-for-delay" agreements, which effectively block generic drug competition; and (2) allow the Federal Trade Commission to initiate proceedings to enforce these restrictions against any parties to such a settlement.The bill also requires drug manufacturers to produce and share annual reports containing specified information related to domestic and foreign sales.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-10-08 00:00:00

Health Insurance Rate Review Act

This bill amends the Public Health Service Act to declare that federal requirements that the Department of Health and Human Services (HHS) review unreasonable premium increases in health care coverage do not prohibit a state from imposing additional rate requirements on health insurance issuers that are more protective of consumers. The review is expanded to include all rate increases, not only premium increases.

HHS or the relevant state insurance commissioner or state regulator must ensure that any excessive, unjustified, or unfairly discriminatory rates are corrected before, or as soon as possible after, implementation, including through mechanisms such as denying rates, modifying rates, or requiring rebates to consumers. HHS may apply civil monetary penalties to health insurance issuers that fail to comply with a corrective action taken by HHS and may make the plan involved ineligible for classification as a qualified health plan.

HHS must determine whether HHS or the state insurance commissioner or regulator will undertake such corrective actions based on whether the state can adequately undertake the actions. This Act applies to health plans grandfathered under the Patient Protection and Affordable Care Act.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-11-18 00:00:00

Protecting Seniors Access to Proper Care Act of 2015

This bill amends title XVIII (Medicare) of the Social Security Act to allow an authorized physician or practitioner who is not enrolled as a Medicare provider to, under certain circumstances, prescribe covered drugs under the Medicare prescription drug benefit. Specifically, the physician or practitioner must not be: (1) otherwise disqualified from being enrolled; or (2) a doctor of medicine or osteopathy, unless the doctor's practice prescribes a low-volume of billings for such drugs under Medicare.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-12-09 00:00:00

Medicare Fair Drug Pricing Act of 2015

This bill amends title XVIII (Medicare) of the Social Security Act to require the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.

Under current law, CMS may not interfere with negotiations between drug manufacturers and prescription drug plan (PDP) sponsors. The bill creates an exception to this prohibition with respect to specified drugs that: (1) are single-source or biological, (2) are not both manufactured by more than two drug manufacturers and manufactured by at least one manufacturer as a generic drug, and (3) meet other specified requirements. CMS must promulgate regulations regarding the identification of such drugs.

With respect to these drugs, CMS shall negotiate the price that may be charged to PDP sponsors and Medicare Advantage (MA) organizations for Medicare and MA enrollees. The bill establishes processes for negotiation and price determination in the initial plan year and subsequent plan years.

A manufacturer must participate in the negotiation process as a condition of coverage under the Medicare prescription drug benefit.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2016-04-29 00:00:00

This bill prohibits the Department of Health and Human Services from taking any further action on a proposed rule to change how Medicare pays for certain drugs that are typically not self-administered (such as some intravenous medications and chemotherapy drugs).
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2016-04-29 00:00:00

This bill amends title XIX (Medicaid) of the Social Security Act to exclude abuse-deterrent formulations of prescription drugs from the requirement that manufacturers of single-source or innovator drugs pay additional rebates to state Medicaid programs.

Under current law, the Centers for Medicare & Medicaid Services (CMS) must use predictive modeling and other analytic technologies to identify improper Medicaid claims. The bill prohibits a state agency from using or disclosing such technologies except for purposes of administering a state Medicaid program or Children's Health Insurance Program (CHIP). A state agency shall have in effect adequate data security and control policies to ensure that access to such information is restricted to authorized persons for authorized uses.

The bill places $5 million in the Medicaid Improvement Fund to be available beginning in FY2021.
Topic: Health — Drug Coverage and Cost
Subject: Armed forces and national security
Date: 2016-09-06 00:00:00

Veterans Preventive Health Coverage Fairness Act

This bill exempts veterans from Department of Veteran Affairs medical copayments for medication or hospital care and medical services related to preventive health services.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2016-09-08 00:00:00

Improving Transparency and Accuracy in Medicare Part D Spending Act

This bill amends title XVIII (Medicare) of the Social Security Act to prohibit Medicare Prescription Drug Plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A "clean claim" is a Medicare claim that is free of defects such as incomplete documentation.)
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2016-09-15 00:00:00

Fair Accountability and Innovative Research Drug Pricing Act of 2016

This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the price of a drug over a 12-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1.

Manufacturers that do not submit a required report are subject to a civil penalty. The Inspector General of HHS must review drug price information to determine compliance. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.

HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2016-09-22 00:00:00

Secondary Payer Advancement, Rationalization, and Clarification Act or the SPARC Act

This bill amends title XVIII (Medicare) of the Social Security Act to specify recovery rules with respect to secondary claims responsibility under the Medicare prescription drug benefit. Under current law, secondary payor provisions apply under the benefit in the same manner as they apply with respect to Medicare Advantage plans.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2016-12-08 00:00:00

Prescription Drug and Medical Device Price Review Board Act of 2016

This bill establishes the Prescription Drug and Medical Device Price Review Board within the Food and Drug Administration. Each manufacturer of a prescription drug or medical device that is sold in the United States must submit to the board:

 each type of prescription drug and medical device that it sells in the United States, or in a country that is a member of the Organization for Economic Co-operation and Development; the price charged by the manufacturer for the drug or device; and the costs of the manufacturer to produce them. The board must establish a formula for determining whether the average manufacturer price of a prescription drug or medical device over an annual quarter is an excessive price. Manufacturers may not charge excessive prices. Individuals may petition the board to determine whether the price for a prescription drug or medical device is excessive.

The board may subject violators to reduced patent terms, civil penalties, and increased Medicaid rebates. The bill amends the Internal Revenue Code to impose a tax on the sale of prescription drugs or medical devices that have excessive prices.

The board must allow individuals to import from approved counties prescription drugs and devices that are comparable to prescription drugs and devices with excessive prices.
Topic: Health — Drug Coverage and Cost
Subject: Health
Date: 2015-01-06 00:00:00

Medicare Prescription Drug Price Negotiation Act of 2015

 Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to direct the Secretary of Health and Human Services to negotiate with pharmaceutical manufacturers the prices that may be charged to Medicare part D prescription drug plan (PDP) sponsors and MedicareAdvantage (MA) organizations for covered part D drugs for part D eligible individuals who are enrolled under a PDP or under an MA-Prescription Drug plan.
Topic: Health — Drug Coverage and Cost
Subject: Armed forces and national security
Date: 2015-01-13 00:00:00

Clay Hunt Suicide Prevention for American Veterans Act or the Clay Hunt SAV Act

 Requires the Secretary of Veterans Affairs (VA) to arrange for an independent third party evaluation, to be conducted by September 30, 2018, and each fiscal year thereafter, of the VA's mental health care and suicide prevention programs.

 Directs the Secretary to survey the VA's websites and information resources to publish a website that serves as a centralized source to provide veterans with information regarding the VA's mental health care services.

 Requires the Secretary to carry out a three-year pilot program to repay the education loans relating to psychiatric medicine that are incurred by individuals who:

 are eligible to practice psychiatric medicine in the Veterans Health Administration (VHA) or are enrolled in the final year of a residency program leading to a specialty qualification in psychiatric medicine; demonstrate a commitment to a long-term career as a psychiatrist in the VHA; and agree to a period of two or more years of obligated service with the VHA in the field of psychiatric medicine. Limits the loan repayment to no more than $30,000 for each year an individual performs such obligated service.

 Directs the Secretary to establish a three-year pilot program at not less than five Veterans Integrated Service Networks (VISNs) to assist veterans transitioning from active duty and to improve the access of veterans to mental health services. Requires the pilot program at each VISN to include: (1) a community oriented veteran peer support network carried out in partnership with an entity that has experience in peer support programs, and (2) a community outreach team for each medical center in such VISN.

Authorizes the Secretary to collaborate with nonprofit mental health organizations to prevent suicide among veterans. Requires the Secretary and any such organization to exchange training sessions and best practices.

Directs the Secretary to select a VA Director of Suicide Prevention Coordination to undertake any collaboration with nonprofit mental health organizations.

Extends for one year combat veterans' eligibility for VA hospital care, medical services, and nursing home care for illnesses that have not been medically proven to be attributable to their service, provided they: (1) were discharged or released from active duty between January 1, 2009, and January 1, 2011, and (2) did not enroll to receive such care during the five-year period of eligibility following their discharge or release.